MP46-07 EFFECT OF A HISTONE DNA DEMETHYLASE ON CRPC CELL LINES, A POTENTIAL THERAPEUTIC APPLICATION.

thenappan chandrasekar,joy c yang,min xie,sheng ding,michael g rosenfeld,christopher p evans

DOI: https://doi.org/10.1016/j.juro.2015.02.1570

2015-01-01

Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research II1 Apr 2015MP46-07 EFFECT OF A HISTONE DNA DEMETHYLASE ON CRPC CELL LINES, A POTENTIAL THERAPEUTIC APPLICATION. Thenappan Chandrasekar, Joy C. Yang, Min Xie, Sheng Ding, Michael G. Rosenfeld, and Christopher P. Evans Thenappan ChandrasekarThenappan Chandrasekar More articles by this author , Joy C. YangJoy C. Yang More articles by this author , Min XieMin Xie More articles by this author , Sheng DingSheng Ding More articles by this author , Michael G. RosenfeldMichael G. Rosenfeld More articles by this author , and Christopher P. EvansChristopher P. Evans More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1570AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen receptor signaling is the key driving force in prostate cancer progression, even in castration-resistant prostate cancer (CRPC). SD70, a competitive inhibitor of KDM4 class of histone demethylases, was demonstrated to have significant inhibitory effect on AR transactivation function in LNCaP cells and androgen-insensitive basal activity in CWR22Rv1. In-vitro assessment of efficacy in CWR22Rv1 cells demonstrated cytotoxity at 5 μM. We aimed to demonstrate the efficacy of SD70 in CRPC cell lines, determine its effect in conjunction with currently approved therapies, and identify a useful biomarker for this novel drug. METHODS Using MTT viability assays, we first assessed SD70 dosing against two CRPC lines (C42B and GRP), then against C42B drug-resistant strains (abiratarone, enzalutamide, abi+enza, docetaxel). For the resistant lines, cells were then treated with 1 μM SD70 in combination with 10 μM abiratarone, 10 μM enzalutamide or 1 nM docetaxel. In vivo drug study was conducted with mouse xenograft models (3 million CWR22Rv1 cells via s.c. injection) in athymic nude mice. When the tumor volume reached 100 mm3, animals were randomly assigned to receive 10 mg/kg SD70 or vehicle via i.p. injection daily. Tumor monitoring was continued until tumor burden exceeded humane endpoint limits indicated by IACUC. RESULTS SD70 demonstrated complete cytotoxic response at 5 μM against C42B and GRP cell lines; IC50 was 2.1 μM and 2.9 μM, respectively. All drug-resistant C42B cell lines were responsive to SD70 treatment; IC50 ranged from 0.90-1.57 μM. SD70 was found to be synergistic with abiratarone, enzalutamide, and docetaxel against drug-resistant C42B and GRP cell lines. In the CWR22Rv1 mouse xenograft model, SD70-treated mice demonstrated significantly lower tumor volume at the end of treatment period (SD70: 507.31±203.72 mm3, control: 2388.01±543.58 mm3); no significant drug toxicity was observed. Expression of AR surrogate markers (PSA, KLK2, TMPRSS2) were diminished in C42B and enzalutamide-resistant C42B lines treated with SD70. No changes in autophagy reporter LC-3 or activation of Akt was observed. CONCLUSIONS SD70 demonstrates promising cytotoxic efficacy against CRPC cells lines in vitro, and appears to have a synergistic effect with currently approved CRPC medications (docetaxel, enzalutamide, and abiratarone) in drug-resistant CRPC lines. Initial in vivo trial demonstrated excellent efficacy against CWR22Rv1 without significant toxicity. Ongoing evaluation into identifying biomarkers will allow for further evaluation of this promising new agent. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e546 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Thenappan Chandrasekar More articles by this author Joy C. Yang More articles by this author Min Xie More articles by this author Sheng Ding More articles by this author Michael G. Rosenfeld More articles by this author Christopher P. Evans More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...